The abstract discusses how popular weight‑loss drugs like tirzepatide, originally for diabetes, are now being used for cosmetic weight loss, creating shortages and high costs for patients who really need them. It highlights ethical issues such as unequal access, safety risks from unregulated alternatives, and the need for doctors, patients, and policymakers to act responsibly.

The emergence of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has transformed the landscape of weight management and diabetes treatment. Initially developed for type 2 diabetes mellitus, these medications have gained widespread popularity due to their weight-loss effects, spurred by media attention and celebrity endorsements. However, their increasing demand raises ethical concerns regarding accessibility, affordability, and medical necessity. Patients with genuine clinical indications often struggle to obtain these medications due to shortages and high costs, while wealthier individuals use them for cosmetic weight loss. Additionally, unregulated alternatives, such as compounded injections and celebrity-endorsed supplements, further complicate the landscape by introducing safety risks and misinformation. Physicians face the challenge of balancing evidence-based prescribing with resource allocation, ensuring medications reach those in need. Patients have a responsibility to critically evaluate information and engage in informed decision-making. Policymakers must address disparities by implementing equitable policies that prioritize medical necessity over commercial interests. As the use of GLP-1 agonists continues to rise, a collaborative approach, rooted in ethical responsibility, patient education, and regulatory oversight, is essential to prevent healthcare inequities and uphold the integrity of medical practice.